Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | May 04, 2020 | May 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date May 04, 2020 · Filed May 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.77 · Expires 2030-05-04 | Direct | 75,000 |
Reported balance
After 2020-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-04 · Grant · Acquired 75,000 · Balance 75,000 F1: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2020 Filed May 6, 2020 22:38 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 75,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004497 · ownership.xml · derivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-05-04 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| May 06, 2019 Filed May 8, 2019 11:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 45,000 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-19-003409 · ownership.xml · derivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-06 F1 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 21:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-005232 · s110812_form4.xml · derivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-12 F1 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 20:05 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 7,500 | $3.33 | $24,975.00 |
DisclosureSEC source: 0001615774-18-004909 · s110676_form4.xml · nonDerivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,470 Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 30,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001615774-17-003292 · s106632_form4.xml · derivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-06-20 F1 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · derivative · entry 4 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · nonDerivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · derivative · entry 5 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · nonDerivative · entry 2 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,845 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:35 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock Purchase Warrant · Derivative | 25,000 | Not disclosed Strike: $0.63 | Not disclosed |
DisclosureSEC source: 0001615774-16-007910 · s104484_form4.xml · derivative · entry 2 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 12,500 shares Expires 2021-10-31 F1 · price: Included in the purchase of 100,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| October 31, 2016 Filed Oct 31, 2016 20:35 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, $0.001 par value | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001615774-16-007910 · s104484_form4.xml · nonDerivative · entry 1 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,196 F1 · price: Included in the purchase of 100,000 Units at a price of $0.55 per Unit. Each Unit consisted of one share of common stock and one warrant exercisable immediately for one-half (0.50) share of common stock at an exercise price of $0.63 per share. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · derivative · entry 6 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001748 · s109296_form4.xml · nonDerivative · entry 3 Rhodes John B · CIK 0001346251 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.